循环肿瘤细胞状态与早期乳腺癌放疗获益及生存的关联
该研究基于NCDB队列和SUCCESS试验,评估早期乳腺癌中循环肿瘤细胞(CTC)状态是否预测放疗获益。CTC阳性患者接受放疗与更长的OS、LRFS和DFS相关,而CTC阴性患者无此获益,提示CTC或可指导放疗决策。
要点
- CTC阳性早期乳腺癌患者接受放疗与更长OS、LRFS和DFS相关
- CTC阴性患者接受放疗未见生存获益
- 保乳术后CTC阳性患者放疗与更长OS相关,乳房切除术后无此关联
核心结论
- 在可检测到CTC的早期乳腺癌患者中,放疗与更长的LRFS、DFS和OS相关。
- 结果仅为假设生成性,需前瞻性试验验证基于CTC的保乳术后放疗管理。
研究设计与样本
- 分析纳入NCDB队列1697例和SUCCESS临床试验1516例pT1-pT2、pN0-pN1且已知CTC状态的乳腺癌患者。
- 采用多变量参数加速失效时间模型评估CTC状态与放疗和生存结局的关联。
主要发现
- NCDB队列CTC阳性399例(23.5%),SUCCESS队列CTC阳性294例(19.4%)。
- NCDB队列4年OS:CTC阳性放疗组94.9% vs CTC阳性未放疗组88.0% vs CTC阴性放疗组93.9% vs CTC阴性未放疗组93.4%(P < .001)。
- SUCCESS队列5年DFS:CTC阳性放疗组88.0% vs CTC阳性未放疗组75.2% vs CTC阴性放疗组92.3% vs CTC阴性未放疗组88.3%(P = .04)。
- NCDB队列CTC阳性患者放疗与更长OS相关(TR 2.04,95%CI 1.55-2.67,P < .001),CTC阴性患者无关联(TR 0.80,95%CI 0.52-1.25,P = .33)。
- SUCCESS队列CTC阳性患者放疗与更长LRFS(TR 2.73,95%CI 1.62-4.80,P < .001)、DFS(TR 3.03,95%CI 2.22-4.13,P < .001)和OS(TR 1.83,95%CI 1.23-2.72,P = .003)相关。
关键数值与推荐
- NCDB队列CTC阳性患者放疗与更长OS相关(TR 2.04,95%CI 1.55-2.67,P < .001)。
- SUCCESS队列CTC阳性患者放疗与更长LRFS(TR 2.73,95%CI 1.62-4.80,P < .001)、DFS(TR 3.03,95%CI 2.22-4.13,P < .001)和OS(TR 1.83,95%CI 1.23-2.72,P = .003)相关。
- 两队列保乳术后CTC阳性患者放疗与更长OS相关(TR 4.37,95%CI 2.71-7.05,P < .001),CTC阴性患者无关联(TR 0.87,95%CI 0.47-1.62,P = .77)。
- 乳房切除术后CTC阳性或阴性患者中放疗均与OS无关联。
临床怎么用
- CTC状态或可作为早期乳腺癌保乳术后放疗决策的参考指标。
- CTC阳性患者可能从放疗中获益更多,CTC阴性患者放疗获益不明确。
- 乳房切除术后患者放疗与OS无关,CTC状态在此场景的指导价值有限。
局限性
- 结果为假设生成性,需前瞻性试验验证CTC指导的放疗管理。
- 研究为队列分析,非随机对照,存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Circulating tumor cells (CTCs) represent the liquid component of solid tumors and are a surrogate marker for residual cancer burden. Although CTC status is prognostic of recurrence and death in breast cancer, its role in guiding clinical management remains unknown. OBJECTIVE: To determine whether CTC status is predictive of radiotherapeutic benefit in early-stage breast cancer. DESIGN, SETTING, AND PARTICIPANTS: The cohort studies in the present analysis included patients with stages pT1 to pT2 and pN0 to pN1 breast cancer and known CTC status from the National Cancer Database (NCDB) and the multicenter phase 3 SUCCESS clinical trial. Multivariable parametric accelerated failure time models were used to evaluate the association of CTC status and radiotherapy (RT) with survival outcomes. Data were collected from January 1, 2004, through December 31, 2014, from the NCDB cohort. The SUCCESS trial collected data from September 1, 2005, through September 30, 2013. The analyses were completed from November 1, 2016, through December 17, 2017. EXPOSURE: Adjuvant RT. MAIN OUTCOMES AND MEASURES: Overall survival (OS), local recurrence-free survival (LRFS), and disease-free survival (DFS). RESULTS: A total of 1697 patients from the NCDB (16 men [0.9%] and 1681 women [99.1%]; median age, 63 years; interquartile range, 53-71 years) and 1516 patients from the SUCCESS clinical trial (median age, 52 years; interquartile range, 45-60 years) were identified. Circulating tumor cells were detected in 399 patients (23.5%) in the NCDB cohort and 294 (19.4%) in the SUCCESS cohort. The association of RT with survival was dependent on CTC status within the NCDB cohort (4-year OS, 94.9% for CTC-positive RT vs 88.0% for CTC-positive non-RT vs 93.9% for CTC-negative RT vs 93.4% for CTC-negative non-RT groups; P < .001) and 5-year DFS within the SUCCESS cohort (88.0% for CTC-positive RT vs 75.2% for CTC-positive non-RT vs 92.3% for CTC-negative RT vs 88.3% for CTC-negative non-RT; P = .04). In the NCDB cohort, RT was associated with longer OS in patients with CTCs (time ratio [TR], 2.04; 95% CI, 1.55-2.67; P < .001), but not in patients without CTCs (TR, 0.80; 95% CI, 0.52-1.25; P = .33). In the SUCCESS cohort, CTC-positive patients treated with RT exhibited longer LRFS (TR, 2.73; 95% CI, 1.62-4.80; P < .001), DFS (TR, 3.03; 95% CI, 2.22-4.13; P < .001), and OS (TR, 1.83; 95% CI, 1.23-2.72; P = .003). Among patients from both cohorts who underwent breast-conserving surgery, RT was associated with longer OS in patients with CTCs (TR, 4.37; 95% CI, 2.71-7.05; P < .001) but not in patients without CTCs (TR, 0.87; 95% CI, 0.47-1.62; P = .77). Radiotherapy was not associated with OS after mastectomy in CTC-positive or CTC-negative patients. CONCLUSIONS AND RELEVANCE: Treatment with RT was associated with longer LRFS, DFS, and OS in patients with early-stage breast cancer and detectable CTCs. These results are hypothesis generating; a prospective trial evaluating CTC-based management for RT after breast-conserving surgery in women with early-stage breast cancer is warranted.
引用
- Goodman CR, Seagle BL, Friedl TWP, et al. Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer. JAMA Oncol. 2018. PMID: 29800954. doi:10.1001/jamaoncol.2018.0163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。